Add a Thiazide-Like Diuretic (Chlorthalidone or Indapamide) to His Amlodipine
For this 71-year-old male with uncontrolled hypertension (160/64) on amlodipine 10 mg, add a thiazide-like diuretic—specifically chlorthalidone or indapamide—as the next step, but monitor his sodium levels closely given his baseline hyponatremia and alcohol use.
Rationale Based on Current Guidelines
The 2025 AHA/ACC guidelines explicitly recommend a three-drug combination for resistant hypertension consisting of an ACE inhibitor or ARB plus a calcium channel blocker (CCB) plus a thiazide-like diuretic 1. Since this patient is already on maximum-dose amlodipine (a CCB), the logical next step is adding either:
- A thiazide-like diuretic (chlorthalidone or indapamide), OR
- An ACE inhibitor or ARB
The 2024 ESC guidelines similarly recommend this triple combination as standard therapy when two-drug combinations fail to control BP 2.
Why Thiazide-Like Diuretic First
The preferred approach is to add a thiazide-like diuretic first because:
- The patient's blood pressure is 160/64—note the wide pulse pressure (96 mmHg), which is characteristic of isolated systolic hypertension common in elderly patients
- Thiazide-like diuretics are particularly effective for isolated systolic hypertension in older adults
- This follows the guideline-recommended sequence toward the standard triple therapy 1, 2
However, there is a critical caveat: The patient has baseline hyponatremia and is an alcoholic. Thiazide and thiazide-like diuretics are well-documented causes of hyponatremia, with the risk being 1.5 times higher in hypertensive patients than the general population 3. Recent meta-analysis data shows increased risk of both hyponatremia (5% vs 3.7%) and hypokalemia (9% vs 7%) with triple combinations containing indapamide 4.
Alternative: Add an ARB or ACE Inhibitor
Given the hyponatremia concern, a safer initial choice would be adding an ARB (such as olmesartan, valsartan, or telmisartan) or an ACE inhibitor because:
- These agents do not worsen hyponatremia
- Multiple studies demonstrate excellent BP reduction when combined with amlodipine 5, 6, 7, 8, 9
- The combination of amlodipine plus ARB achieved BP control in 72-75% of patients with uncontrolled hypertension 5
- Single-pill combinations improve adherence
Specific Recommendations
If Sodium is Mildly Low (130-134 mmol/L):
- Start with an ARB: Olmesartan 20 mg, valsartan 160 mg, or telmisartan 40-80 mg
- This avoids worsening hyponatremia while moving toward triple therapy
- Monitor BP response over 4-8 weeks
- If still uncontrolled, cautiously add low-dose chlorthalidone (12.5 mg) or indapamide (1.25 mg) with close sodium monitoring
If Sodium is Normal or Near-Normal (≥135 mmol/L):
- Add chlorthalidone 12.5-25 mg or indapamide 1.25-2.5 mg
- Monitor sodium and potassium levels within 2-4 weeks
- Address alcohol use, as this contributes to hyponatremia risk
Alcohol Use Consideration:
- Chronic alcohol use causes hyponatremia through multiple mechanisms (beer potomania, SIADH, malnutrition)
- Counsel on alcohol cessation—the 2024 ESC guidelines recommend avoiding alcohol consumption for best health outcomes 2
- Alcohol cessation alone may improve both BP and sodium levels
Monitoring Requirements
When adding any agent to this patient:
- Check sodium and potassium within 2-4 weeks of starting therapy
- Recheck BP in 4 weeks
- If using a diuretic with baseline hyponatremia, consider weekly sodium checks initially
- Watch for symptoms of worsening hyponatremia (confusion, falls, nausea)
The Complete Triple Therapy Goal
The ultimate goal per guidelines is achieving the combination of RAS blocker (ACE-I or ARB) + CCB (amlodipine) + thiazide-like diuretic 1, 2. The question is simply the order of addition given this patient's hyponatremia:
- Lower risk approach: Add ARB first, then add diuretic if needed
- Standard approach: Add thiazide-like diuretic with close monitoring
Both the 2025 AHA/ACC and 2024 ESC guidelines emphasize that if BP remains uncontrolled on this triple therapy, the next step would be adding a mineralocorticoid receptor antagonist (spironolactone or eplerenone) if eGFR ≥45 mL/min/1.73 m² 1.